FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2952088051> ?p ?o ?g. }

• W2952088051 abstract "Background For patients with Rheumatoid Arthritis (RA) who do not achieve adequate clinical response with combined conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs), the next step in goal-directed therapy is initiation of either biologic DMARDs (bDMARDs) or targeted synthetic DMARDs (tsDMARDs). bDMARDs include tumour-necrosis factor inhibitors (TNFi) or non-TNFi classes. Since inception of Ontario Best Practice Research Initiative (OBRI), new treatment options have become available Objectives We aimed to describe the evolution of relative use of non-TNFi vs. TNFi in Ontario-based practices from 2008-2017. Methods Adult patients with RA enrolled in the OBRI who started therapy with bDMARDs or tsDMARDs anytime during, or up to 30 days before, enrollment were included. Using descriptive analysis of data from each year between 2008 and 2017, the relative proportion of the population treated with TNFi and non-TNFi therapy was measured for (i) all patients and (ii) those initiating their first bDMARD/tsDMARD. TNFi included: Etanercept, Adalimumab, Certolizumab, Golimumab, and Infliximab. Non-TNFi included: Abatacept, Rituximab, Tocilizumab, and Tofacitinib. Results A total of 1,057 patients were included of whom 653 were bDMARD/tsDMARD naive. In 2008, the relative non-TNFi use was 3/56 (5.4%) in all patients and 0/31 (0%) in treatment-naive patients. By 2013 the proportion non-TNFi use increased to 135/562 (24%) in all patients and 11/92 (12.0%) in treatment-naive patients. This increasing trend in relative non-TNFi utilization continued in both groups until 2016 when relative use was 224/679 (33.0%) in all patients and 17/56 (30.4%) in treatment-naive. This was followed by 144/426 (33.8%) and 4/15 (26.7%), respectively in 2017. Conclusion This descriptive analysis of data from the OBRI cohort shows an increase in the use of non-TNFi therapies. The overall trend towards greater use of non-TNFi therapies as first line agents after combined csDMARDs may be partially explained by the presence of guidelines that allow clinicians to select any of the above options as first line advanced therapies. Future analyses evaluating patient-, disease- and concomitant drug use-specific determinants of physician decision-making will be conducted. Acknowledgement Drs. Ahluwalia, V., Ahmad, Z., Akhavan, P., Albert, L., Alderdice, C., Aubrey, M., Aydin, S., Bajaj, S., Bensen, B., Bhavsar, S., Bobba, R., Bombardier, C., Bookman, A., Cabral, A., Carette, S., Carmona, R., Chow, A., Ciaschini, P., Cividino, A., Cohen, D., Dixit, S., Haaland, D., Hanna, B., Haroon, N., Hochman, J., Jaroszynska, A., Johnson, S., Joshi, R., Kagal, A., Karasik, A., Karsh, J., Keystone, E., Khalidi, N., Kuriya, B., Larche, M., Lau, A., LeRiche, N., Leung, Fe., Leung, Fr., Mahendira, D., Matsos, M., McDonald-Blumer, Midzic, I., Milman, N., H., Mittoo, S., Mody, A., Montgomery, A., Mulgund, M., Ng, E., Papneja, T., Pavlova, P., Perlin, L., Pope, J, Purvis, J., Rohekar, G., Rohekar, Ruban, T., S., Samadi, N., Shaikh, S., Shickh, A., Shupak, R., Smith, D., Soucy, E., Stein, J., Thompson, A., Thorne, C., Wilkinson, S. Disclosure of Interests Elliot Hepworth: None declared, Mohammad Movahedi: None declared, Emmanouil Rampakakis : None declared, Reza Mirza: None declared, Arthur Lau: None declared, Angela Cesta: None declared, Janet Pope Consultant for: Eli Lilly and Company, Claire Bombardier Grant/research support from: Abbvie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Hospira, Janssen, Merck, Novartis, Pfizer Inc, Roche, Sanofi, UCB, Consultant for: AbbVie, Hospira, Janssen, Merck, Novartis, Pfizer Inc, Sanofi, Speakers bureau: Roche" @default.
• W2952088051 created "2019-06-27" @default.
• W2952088051 creator A5023213876 @default.
• W2952088051 creator A5024492944 @default.
• W2952088051 creator A5036952384 @default.
• W2952088051 creator A5069216403 @default.
• W2952088051 creator A5069410791 @default.
• W2952088051 creator A5072082104 @default.
• W2952088051 creator A5080491966 @default.
• W2952088051 creator A5083810857 @default.
• W2952088051 date "2019-06-01" @default.
• W2952088051 modified "2023-09-27" @default.
• W2952088051 title "THU0163 A DESCRIPTIVE ANALYSIS OF LONGITUDINAL CHANGES IN RELATIVE MARKET SHARE PROPORTIONS OF BIOLOGIC AND TARGETED SYNTHETIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS FOR TREATMENT OF RHEUMATOID ARTHRITIS: DATA FROM THE OBRI DATABASE" @default.
• W2952088051 doi "https://doi.org/10.1136/annrheumdis-2019-eular.8100" @default.
• W2952088051 hasPublicationYear "2019" @default.
• W2952088051 type Work @default.
• W2952088051 sameAs 2952088051 @default.
• W2952088051 citedByCount "0" @default.
• W2952088051 crossrefType "proceedings-article" @default.
• W2952088051 hasAuthorship W2952088051A5023213876 @default.
• W2952088051 hasAuthorship W2952088051A5024492944 @default.
• W2952088051 hasAuthorship W2952088051A5036952384 @default.
• W2952088051 hasAuthorship W2952088051A5069216403 @default.
• W2952088051 hasAuthorship W2952088051A5069410791 @default.
• W2952088051 hasAuthorship W2952088051A5072082104 @default.
• W2952088051 hasAuthorship W2952088051A5080491966 @default.
• W2952088051 hasAuthorship W2952088051A5083810857 @default.
• W2952088051 hasBestOaLocation W29520880511 @default.
• W2952088051 hasConcept C126322002 @default.
• W2952088051 hasConcept C1862650 @default.
• W2952088051 hasConcept C2776215756 @default.
• W2952088051 hasConcept C2777138892 @default.
• W2952088051 hasConcept C2777178219 @default.
• W2952088051 hasConcept C2777226972 @default.
• W2952088051 hasConcept C2777575956 @default.
• W2952088051 hasConcept C2778886723 @default.
• W2952088051 hasConcept C2779134260 @default.
• W2952088051 hasConcept C2779338263 @default.
• W2952088051 hasConcept C2779605438 @default.
• W2952088051 hasConcept C2780132546 @default.
• W2952088051 hasConcept C2780653079 @default.
• W2952088051 hasConcept C2781290027 @default.
• W2952088051 hasConcept C2908564923 @default.
• W2952088051 hasConcept C2908647359 @default.
• W2952088051 hasConcept C2909063479 @default.
• W2952088051 hasConcept C71924100 @default.
• W2952088051 hasConcept C99454951 @default.
• W2952088051 hasConceptScore W2952088051C126322002 @default.
• W2952088051 hasConceptScore W2952088051C1862650 @default.
• W2952088051 hasConceptScore W2952088051C2776215756 @default.
• W2952088051 hasConceptScore W2952088051C2777138892 @default.
• W2952088051 hasConceptScore W2952088051C2777178219 @default.
• W2952088051 hasConceptScore W2952088051C2777226972 @default.
• W2952088051 hasConceptScore W2952088051C2777575956 @default.
• W2952088051 hasConceptScore W2952088051C2778886723 @default.
• W2952088051 hasConceptScore W2952088051C2779134260 @default.
• W2952088051 hasConceptScore W2952088051C2779338263 @default.
• W2952088051 hasConceptScore W2952088051C2779605438 @default.
• W2952088051 hasConceptScore W2952088051C2780132546 @default.
• W2952088051 hasConceptScore W2952088051C2780653079 @default.
• W2952088051 hasConceptScore W2952088051C2781290027 @default.
• W2952088051 hasConceptScore W2952088051C2908564923 @default.
• W2952088051 hasConceptScore W2952088051C2908647359 @default.
• W2952088051 hasConceptScore W2952088051C2909063479 @default.
• W2952088051 hasConceptScore W2952088051C71924100 @default.
• W2952088051 hasConceptScore W2952088051C99454951 @default.
• W2952088051 hasLocation W29520880511 @default.
• W2952088051 hasOpenAccess W2952088051 @default.
• W2952088051 hasPrimaryLocation W29520880511 @default.
• W2952088051 hasRelatedWork W2415874162 @default.
• W2952088051 hasRelatedWork W2755211682 @default.
• W2952088051 hasRelatedWork W2755296718 @default.
• W2952088051 hasRelatedWork W2756208004 @default.
• W2952088051 hasRelatedWork W2899761268 @default.
• W2952088051 hasRelatedWork W2947615217 @default.
• W2952088051 hasRelatedWork W2949268801 @default.
• W2952088051 hasRelatedWork W2949483997 @default.
• W2952088051 hasRelatedWork W2950701826 @default.
• W2952088051 hasRelatedWork W2952770421 @default.
• W2952088051 hasRelatedWork W3033227632 @default.
• W2952088051 hasRelatedWork W3033554912 @default.
• W2952088051 hasRelatedWork W3034582727 @default.
• W2952088051 hasRelatedWork W3034647015 @default.
• W2952088051 hasRelatedWork W3041179836 @default.
• W2952088051 hasRelatedWork W3082566691 @default.
• W2952088051 hasRelatedWork W3093094066 @default.
• W2952088051 hasRelatedWork W3096940001 @default.
• W2952088051 hasRelatedWork W3163972234 @default.
• W2952088051 hasRelatedWork W3165884485 @default.
• W2952088051 isParatext "false" @default.
• W2952088051 isRetracted "false" @default.
• W2952088051 magId "2952088051" @default.
• W2952088051 workType "article" @default.